Achalasia in a Poor Surgical Candidate: Botulinum Toxin or Nitrates/CCBs
With definitive therapy ruled out by severe cardiopulmonary disease, achalasia management for this patient comes down to two genuinely different pharmacologic bridges — botulinum toxin injected directly at the lower esophageal sphincter, or oral smooth-muscle relaxants that work systemically but never as durably.
Eleanor V., 79, has lived in the same assisted-living apartment for six years since her husband passed, close enough to walk to the dining hall three times a day — a routine that has become genuinely difficult as swallowing solid food, then eventually soft food, has grown harder over the past year. Manometry confirmed Type II achalasia, with elevated integrated relaxation pressure and panesophageal pressurization on swallowing. She has severe COPD on 2L home oxygen and a recent non-ST-elevation MI eight months ago with a residual ejection fraction of 35% — comorbidity severe enough that both pneumatic dilation and surgical (or peroral endoscopic) myotomy, the two definitive options with the best durability data, were declined by both her cardiologist and pulmonologist as carrying unacceptable procedural risk.
That leaves two real pharmacologic options, neither of them definitive, and each with a genuinely different profile. Botulinum toxin injected endoscopically directly into the lower esophageal sphincter blocks presynaptic acetylcholine release at that one site, producing real symptomatic improvement in most patients for a period usually measured in months rather than years before it wanes and requires re-injection — still an endoscopic procedure, though a far lower-risk one than dilation or myotomy. Oral nitrates or calcium channel blockers work systemically rather than locally, relaxing esophageal smooth muscle the same way they relax vascular smooth muscle, which is precisely the problem: in a patient this cardiac-fragile, the vasodilation and hypotension risk from a drug class already central to her own cardiac regimen is a real, mechanism-based concern, not a hypothetical one.
"Usually months" has a number attached to it: Pasricha and colleagues' long-term follow-up found roughly two-thirds of patients still in remission at six months, with that fraction falling further over the following year and most eventual relapses requiring re-injection — a real, if temporary, benefit rather than a durable fix, and part of why the group discussed re-injection planning explicitly rather than treating a single injection as the end of the conversation.
Choosing between two non-definitive options
Given that both definitive options are off the table, I'd recommend endoscopic botulinum toxin injection at the LES. It works locally — blocking presynaptic acetylcholine release right at the site of the problem — rather than systemically, which matters a great deal in someone this cardiac-fragile. It's a genuinely lower-risk procedure than the dilation and myotomy cardiology and pulmonology already declined, and most patients get real symptomatic relief, even knowing it usually wanes over months and needs re-injection.
I want to flag something specific about the oral alternative, since it's worth ruling out clearly rather than by default: she's already on a nitrate as part of her post-MI regimen. Adding a second nitrate, or a calcium channel blocker, for achalasia would layer additive vasodilation and hypotension risk onto a patient with an EF of 35% — the same mechanism, doubled, in someone who can't tolerate a significant blood pressure drop.
That's exactly the argument for botulinum toxin's local mechanism here — it sidesteps that specific interaction entirely rather than trying to dose around it.
I don't disagree with either of you on the mechanism, but I want us to be consistent. We declined dilation and myotomy because of her cardiopulmonary status, and botulinum injection is still an endoscopic procedure requiring sedation in a patient on continuous home oxygen with a recent MI. It's a meaningfully lower risk than what we already declined, and I'll support it — but I want that acknowledged directly rather than treated as risk-free just because it's the lower-risk option on the table.
Given the direct, predictable hypotension risk the pharmacologist named with a second nitrate or CCB, botulinum toxin is still the safer of the two remaining choices, even with real procedural risk of its own.
Agreed: endoscopic botulinum toxin injection at the LES, performed with continuous cardiac monitoring and cardiology present for the procedure, given the residual sedation and vasovagal risk the cardiologist named directly.
Not fully settled: how soon re-injection should be offered once symptoms recur, versus revisiting whether her cardiopulmonary status might have improved enough by then to reconsider a more definitive option. That question was deliberately left open for her next follow-up rather than decided preemptively today.